In Pursuit of Unicorns: A Journey through 50 Years of Biotechnology, Updated Edition

Tim Harris
Skip to product information

In Pursuit of Unicorns: A Journey through 50 Years of Biotechnology, Updated Edition

Tim Harris
Release date:
Regular price $55.95
Sale price $55.95 Regular price $0.00
Final Sale. No returns or exchanges.
Oversized: This item will be shipped by appointment through our delivery partner.
Overweight: This item will be shipped by appointment through our delivery partner.

Digital download

Immediate access in your Kobo library

Deliver to

In stock online. Free shipping on orders over $49

Buy online, pick up at Bay & Floor

Free pick up today

Find it in store

Out of stock

Found in: Science & Nature, General Science

Earn 280 plum points and save more with plum Rewards. Learn more

View full details

Overview

548 PAGESENGLISH

Promotional Details
“Unicorns takes the reader on a fascinating journey from the beginnings of recombinant DNA technology to today's cutting-edge science and novel therapies. Few people have been part of this extraordinary expedition the way the author has and no one has shared his experiences in such a lucid and captivating style.” -- Stelios Papadopoulos, ex-Chairman of Biogen and a former biotech investment banker with SG Cowen and PaineWebber
  • Published date: Mar 03, 2026
  • Language: English
  • No. of Pages: 548
  • Publisher: Cold Spring Harbor Laboratory Press
  • ISBN: 9781621825616
  • Dimensions: 6.0" W x 1.0" L x 9.0" H
Dr. Tim Harris is a molecular biologist and biochemist. He started work in the biotech industry almost at its inception. He began his career in 1974, working on animal viruses, and was one of the first scientists to join the U.K. biotech company Celltech in 1981. Subsequently he spent nearly five years at Glaxo Group Research (now GSK) in the United Kingdom as Director of Biotechnology. Tim has founded several biotech companies since moving to the United States in 1993 to be head of R&D at Sequana Therapeutics, a genomics company in San Diego. He founded and ran SGX Pharmaceuticals (acquired by Eli Lilly) and served briefly as the Chief Technology Officer (CTO) and Director of the Advanced Technology Program (ATP) at SAIC-Frederick, Inc. in Maryland. Latterly, Tim moved to Biogen as SVP Translational Medicine in 2011, before joining the haematology spinout Bioverativ, as head of R&D in March 2017 before the company was acquired by Sanofi. Tim is presently a venture partner at SV Health Investors and actively works on behalf of several small biotechnology companies, some of which he founded. He has published more than 100 peer-reviewed research papers and reviews and has written many commentaries for BioCentury and other industry magazines.

Recently Viewed